The cost of lung cancer management in France from the payor's perspective

Disease Management and Health Outcomes

Volumn 14, Issue 1, 2006, Pages 55-67

  Vergnenègre, Alain ^a,f,g,h,i   Molinier, Laurent ^b   Combescure, Christophe ^c   Daurès, Jean Pierre ^c   Housset, Bruno ^d   Chouaïd, Christos ^e  

^a Hopital du Cluzeau   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f Department of Epidemiology and Health Economics   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h Lung Disease Department on Clinical Trials on Lung Cancer   (France)

ⁱ Cooperative Oncologic Group on Lung Cancer ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT;

AGED; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG COST; FRANCE; HEALTH CARE COST; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRINCIPAL COMPONENT ANALYSIS; PRIVATE HOSPITAL; PUBLIC HOSPITAL; REVIEW; SENSITIVITY ANALYSIS; TERMINAL CARE;

EID: 32644448128     PISSN: 11738790     EISSN: 11738790     Source Type: Journal    
DOI: 10.2165/00115677-200614010-00007     Document Type: Review

References (34)

1. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4 (5): 1087-100
2. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998; 16 (12): 3900-12
3. Bishop JF, Macarounas-Kirchman K. The pharmacoeconomics of cancer therapies. Semin Oncol 1997; 24 (6): S106-11
4. Berthelot JM, Will BP, Evans WK, et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 2000; 92 (16): 1321-9
5. Evans WK, Will BP, Berthelot JM, et al. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 1995; 72 (5): 1270-7
6. Evans WK, Will BP, Berthelot J. Cost-effectiveness of lung cancer treatment. In: Hansen HH, editor. Textbook on lung cancer. London: Mosby, 2000: 349-62
7. Desch CE, Hillner BE, Smith TJ. Economic considerations in the care of lung cancer patients. Curr Opin Oncol 1996; 8 (2): 126-32
8. Koopmannschap MA, Rutten FH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10 (5): 460-6
9. Evans WK, Will BP, Berthelot JM, et al. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol 1995; 5 (4): 408-19
10. Hillner BE, McDonald MK, Desch CE, et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol 1998; 16 (4): 1420-4
11. Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 1999; 80 (1-2): 215-8
12. Chouaid C, Molinier L, Combescure C, et al. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004; 90 (2): 397-402
13. Smith TJ, Hillner BE, Neighbors DM, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13 (9): 2166-73
14. Vergnenegre A, Perol M, Pham E. Cost analysis of hospital treatment: two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Francais Pneumo Cancerologie). Lung Cancer 1996; 14 (1): 31-44
15. Borella L, Peuvrel P, Sauvage M, et al. Un essai d'exploitation de la base PMSI nationale pour évaluer le volume et les modes de prise en charge du cancer en secteur hospitalier non lucratif. Rev Epidemiol Sante Publique 2000; 48 (1): 53-70
16. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996-3018
17. Federation Nationale des Centres de Lutte Contre le Cancer. Standards, options, recommandations pour la prise en charge thérapeutique des patients atteints d'un cancer broncho-pulmonaire non à petites cellules localement avancé. Bull Cancer 2001; 88: 369-87
18. Harris PL. Etude Cancérologie 1997. Paris: Harris ed, 1998
19. Oliver E, Killen J, Kiebert G, et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001; 56 (10): 785-90
20. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13 (4): 322-38
21. Launois R, Croutsche JJ, Megnigbeto AC, et al. L'apport indispensable de l'épidémiologie clinique aux mod̀eles de Markov. J Econ Med 1999; 17 (5): 343-61
22. Marshall D, Simpson KN, Earle CC, et al. Economic decision analysis model of screening for lung cancer. Eur J Cancer 2001; 37 (14): 1759-67
23. Drummond MF, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press, 1990
24. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296 (13): 716-21
25. UCANSS. Nomenclature Générale des Actes Professionnels des Médecins, Chirurgiens-dentistes, Sages-femmes et Auxiliaires médicaux. Nomenclature des actes de biologie médicale. CNAMTS ed 2003; 1
26. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly? Ann Intern Med 1992; 116 (3): 238-44
27. Launois R, Vergnenegre A, Garrigues B. Notions et mesure des coûts en fonction de la perspective choisie. Bull Cancer 2003; 90 (11): 946-54
28. Evans WK, Will BP, Berthelot JM, et al. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 1997; 15 (9): 3038-48
29. Earle CC, Evans WK. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 1999; 80 (5-6): 815-20
30. Evans WK. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module. Semin Oncol 1997; 24 (2 Suppl. 7): 56-63
31. Evans WK, Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer 1996; 32A (13): 2249-55
32. Dedes KJ, Szucs TD, Bodis S, et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 2004; 22 (7): 435-44
33. Evans WK, Dahrouge S, Stapleton J, et al. An estimate of the cost of conducting phase II trials in lung cancer. Lung Cancer 2000; 28 (2): 85-95
34. Blanchon F, Grivaux M, Collon T, et al. Epidémiologie du cancer bronchique primitif pris en charge dans les centres hospitaliers généraux français. Rev Mal Respir 2002; 19 (6): 727-34